MacroGenics IncChange company Symbol lookupSelect an option...MGNX MacroGenics IncSMSMY Sims LtdDHCAU DHC Acquisition CorpBCH Banco de ChileNLRCF Northern Lights Resources CorpABM ABM Industries IncLVOXW LiveVox Holding Equity Warrants Exp 18 June 2026 *W EXP 06/18/2026TY- Tri-Continental CorpBAC Bank of America CorpKLXE KLX Energy Services Holdings IncGo
MacroGenics, Inc. is a biopharmaceutical company that is focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. It is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.
|
|
|
|
| |
Upcoming Events
Past Earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
| Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
|---|---|---|---|---|
| May 3, 2022 | Q1 2022 Earnings Release | -$1.08 | -$1.03 to -$0.68 | -$0.90 |
| February 24, 2022 | Q4 2021 Earnings Release | -$0.95 | -$1.00 to -$0.71 | -$0.04 |
| November 2, 2021 | Q3 2021 Earnings Release | -$0.86 | -$0.90 to -$0.14 | -$0.66 |
| July 29, 2021 | Q2 2021 Earnings Release | -$0.66 | -$1.03 to $1.45 | -$0.94 |
Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.
, , , Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.